CTBP2 and hepatocellular carcinoma: In addition, in uterus, breast, and hepatocellular cancers MDSCs can promote the emergence and maintenance of the CSC phenotype in several ways (e.g., C-terminal binding protein 2 /CtBP2/ inhibition by micro-ribonucleic acid (miRNA)10 1; increased prostaglandin E2 (PGE2) production; increased IL6 and nitric oxide (NO) production by involving the STAT3 signaling) [55,56,57,58].